NY-DRIVEWEALTH
22.12.2022 15:01:40 CET | Business Wire | Press release
DriveWealth, LLC, a global fintech investment rail and pioneer in fractional investing, today announced that following its milestone year of rapid global expansion, customer growth, and product innovation, the company has been recognized for its achievements as the category leader that is redefining investing through 10 of the most prominent industry awards. Each of these lists recognize the world’s most innovative and influential businesses and include:
- Industry awards: This year, the firm was named to the CB Insights Fintech 250 for the second consecutive year, the 2022 Deloitte Technology Fast 500, the 2022 Forbes Fintech 50, the WealthTech 100, and the Benzinga 2022 Global Fintech Awards, among others. Emily Ellis, Head of People, was also recognized with an Inspiring Fintech Female Award from NYC Fintech Women.
- Product awards: DriveWealth recently partnered with Adaptive Financial Consulting to build a new proprietary order management system (OMS) to address increased demand in its retail brokerage business. This high-throughput, low-latency OMS, which leverages Aeron technology, was recognized as 2022’s Best Collaboration/Alliance Initiative by Waters Technology’s American Financial Technology Awards.
- Workplace awards: The firm was listed as a 2022 New Jersey Top Workplace. Built In also honored the firm in its Best Places To Work Awards as one of its Best Midsize Companies to Work For and Best Paying Companies in New York City for the second consecutive year.
“Our solutions are transforming the investing landscape and we’re honored to see such positive industry recognition for our work,” said Bob Cortright, Founder of DriveWealth. “DriveWealth’s significant global growth this year can be directly attributed to the flexible scalability and customization of our platform’s APIs. We look forward to remaining the primary industry choice for fintechs who are looking to empower their customers with innovative investing solutions worldwide.”
These industry accolades built upon a number of milestones that DriveWealth achieved in 2022, including:
- Grew its global footprint: DriveWealth built upon key partnerships in Europe (Bank of Georgia) and Asia Pacific (Toss Securities), in addition to launching new partnerships in underserved markets such as Africa (Chipper Cash) and Latin America (Sproutfi) to expand affordable access to investing. In addition to notable new partnerships, DriveWealth expanded its global footprint by establishing presences in Singapore, London, Dublin, Lithuania, and Brazil to support partners and retail investors globally.
- Bolstered its innovative suite of services: DriveWealth’s Fracker®, its proprietary OMS that has reinvented the retail investing experience for millions worldwide, was granted a patent by the U.S. Patent and Trademark Office. In addition to launching two wholly-owned subsidiaries, DriveDigital and DriveLiquidity, to offer cryptocurrency capabilities to partners and their retail investors, the company launched its Developer Dashboard to enable developers to gain free, instant access to the same resilient and scalable APIs that DriveWealth’s partners access in a sandbox environment. Finally, the firm expanded its DriveAdvisory platform, a technology infrastructure solution that empowers partners to fully integrate financial advisory products into their existing apps.
DriveWealth anticipates significant opportunities for growth in 2023, supported by results included in its proprietary DriveTrends report, which showed that digital trading became increasingly popular this year among global Millennials even amid 2022 market lows – a trend expected to continue into 2023. The study analyzed data from more than 12 million investors worldwide who trade fractional shares of U.S. equities through DriveWealth’s network of 100+ global partners, including MoneyLion, Revolut, Grupo Bursátil Mexicano (GBM), and Goalsetter, among others.
About DriveWealth
DriveWealth, a global fintech investment rail and pioneer of fractional equities trading, is a visionary technology company that empowers more than 100 partners around the world to engage their customers by placing the markets in the palm of their hands. We believe the future is fractional, transactional and mobile. Every mobile device should be a gateway to accessing investing and savings products, services, advice, and assistance for global citizens of all ages, wealth stages, and levels of financial expertise. DriveWealth’s consultative support and cloud-based, modern technology platform allow partners to seamlessly offer branded investing experiences to drive customer acquisition, loyalty, retention, and revenue growth. For more information, please visit drivewealth.com or connect with us on Twitter @DriveWealth or on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221222005077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom